Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma &nbsp CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced data from the Phase 1 dose escalatio..

• format_list_bulleted Pharmacology/BS
• · 2023. 6. 29.
• textsms

APX3330 ZETA-1 Clinical Data Presented at American Diabetes Association’s Annual Conference

Ocuphire Pharma, Inc. presented clinical data on their drug APX3330 in a late-breaker session at the American Diabetes Association's Annual Conference. The data showed that APX3330 reduced the worsening of diabetic retinopathy after 24 weeks of treatment. This could potentially shift the treatment paradigm for diabetic retinopathy and broaden the prescriber base to include primary care and endoc..

• format_list_bulleted Pharmacology/BS
• · 2023. 6. 28.
• textsms